Biggest News Aggregation in the World
📰 Thyroid Disorders News

Page 3 - Thyroid Disorders News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Thyroid Disorders. Real-time updates on events, politics, business and more.

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023
United Kingdom United States Johnv Heymach Le Chevalier Daiichi Sankyo Susan Galbraith

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

Results from Phase 3 KEYNOTE-966 to be presented at AACR 2023 Annual Meeting during Clinical Trials Plenary Session, included in official meeting press program and published simultaneously in The... | April 16, 2023
United States San Francisco Robin Kate Kelley Merck Co Inc Statement Of Merck Co Inc Exchange Commission

Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coform

Blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel aloneRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe...
United States Julie Cunningham Nikki Sullivan Peter Dannenbaum Damini Chokshi Eliav Barr

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

AstraZeneca: IMFINZI (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up

HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial
France General Soult Ukpyolsi South Korea United States United Kingdom Jessica Mcduell

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science